Syngulon

Syngulon is a Belgium-based synthetic biology company leveraging bacteriocins to create novel genetic tools for industrial biotechnology and healthcare. Operating as a 'Startup in the Labs,' it collaborates closely with academic partners across Europe and the US to develop its PARAGEN collection of natural and synthetic bacteriocins. The company's platform addresses critical industry challenges including the need for antibiotic-free biomanufacturing, robust contamination control, and new antimicrobials to combat rising resistance. Its approach is underpinned by a distinguished Scientific Advisory Board with deep expertise in microbiology and bacterial genetics.

Synthetic biology platform for engineering bacteriocins (ribosomally-produced antimicrobial peptides). The company is building the PARAGEN collection of natural and synthetic bacteriocins to develop tools for antibiotic-free genetic selection, precision bioprocess contamination control, and next-generation antimicrobial therapeutics.

In antimicrobials, Syngulon competes with other biotechs developing novel peptides, phage therapies, and other non-traditional anti-infectives. In industrial biotech tools, it faces competition from companies offering alternative selection systems (e.g., based on auxotrophy or other genetic markers) and broad-spectrum biocides for contamination control. Its differentiated focus on engineered, narrow-spectrum bacteriocins is a key competitive angle.